Saxenda for NASH: Off-Label Evidence Summary

What Is Saxenda and Why Is It Used Off-Label for NASH?

Saxenda is the brand name for liraglutide 3 mg/day, a subcutaneous GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with a body mass index of 30 or higher, or 27 or higher in the presence of at least one weight-related condition such as type 2 diabetes or hypertension. It is not approved for NASH. Physicians prescribe it off-label for NASH patients primarily because obesity and insulin resistance drive the disease, and meaningful weight reduction, typically 7 to 10 percent of body weight, is the only consistently effective lifestyle-based intervention to improve liver histology.

NASH (nonalcoholic steatohepatitis) is the inflammatory, progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD). Left untreated, it can advance to cirrhosis and hepatocellular carcinoma. Until resmetirom gained FDA approval in March 2024 for noncirrhotic NASH with stage F2 or F3 fibrosis, there were no approved pharmacologic treatments, leaving clinicians to use agents approved for related conditions, including GLP-1 receptor agonists like liraglutide, off-label. [1]

The Regulatory Distinction

Off-label prescribing is legal and common in the United States. The FDA approved Saxenda under NDA 206321 for weight management, not liver disease. Prescribing it for NASH requires informed consent documentation noting the off-label use, and insurers frequently decline coverage for this indication. Patients should understand that the evidence base, while encouraging, rests on a single phase 2 randomized controlled trial with 52 participants, not the phase 3 multicenter data the FDA requires for a formal NASH indication.

How NASH Differs from Simple Steatosis

Simple steatosis (fatty liver without inflammation) carries low fibrosis risk. NASH is defined by the presence of hepatocyte ballooning, lobular inflammation, and steatosis on biopsy, with or without fibrosis. The NAFLD Activity Score (NAS) quantifies these features. A NAS reduction of 2 or more points with no fibrosis worsening is the standard histologic endpoint used in NASH trials, including the LEAN trial. [2]

The LEAN Trial: Primary Evidence for Liraglutide in NASH

The LEAN trial (Liraglutide Efficacy and Action in NASH) is the single published phase 2 RCT examining a GLP-1 agonist specifically in biopsy-proven NASH. Armstrong and colleagues randomized 52 adults with biopsy-confirmed NASH to liraglutide 1.8 mg/day or placebo for 48 weeks. Both groups received standard lifestyle counseling. The primary endpoint was histologic resolution of NASH on end-of-treatment biopsy.

Histologic Outcomes

NASH resolution occurred in 39% of liraglutide-treated participants versus 9% of those on placebo (P=0.019). [3] Fibrosis worsening, a secondary safety endpoint, was observed in 9% of the liraglutide group compared with 36% of the placebo group. No participant in the liraglutide arm showed progression of fibrosis stage by more than one point.

The NAS decreased by a mean of 1.3 points in the liraglutide arm versus 0.5 points in the placebo arm. Hepatocyte ballooning, the feature most strongly linked to fibrosis progression, improved in 30% of the liraglutide group versus 15% of controls.

Metabolic and Weight Outcomes

Mean body weight fell by 5.5% in the liraglutide arm compared with 0.5% in placebo. Alanine aminotransferase (ALT) declined by a mean of 26 IU/L from baseline in liraglutide patients. Fasting plasma glucose dropped by a mean of 1.1 mmol/L, and HbA1c fell by 0.6 percentage points in those with type 2 diabetes at baseline. [3]

These metabolic improvements are clinically meaningful but correlate imperfectly with histologic change. Not every participant who lost weight showed histologic resolution, and not every participant with histologic improvement met the 5% weight-loss threshold. This dissociation suggests liraglutide may have direct hepatic effects beyond weight reduction alone.

What LEAN Does Not Tell Us

The trial used liraglutide 1.8 mg/day, the dose approved for type 2 diabetes (Victoza), not the 3 mg/day dose used in Saxenda. No published RCT has evaluated liraglutide 3 mg specifically in biopsy-proven NASH. Whether the higher dose produces superior histologic outcomes is biologically plausible given the dose-response relationship seen in weight-loss studies, but it remains unconfirmed by controlled data. [4]

The sample size of 52 gives the trial limited statistical power to detect fibrosis improvements as a primary endpoint, and the 48-week duration may not capture long-term fibrosis regression. LEAN was not powered to assess hard clinical outcomes such as liver-related mortality or transplant-free survival.

Mechanism of Action in NASH

GLP-1 receptors are expressed in the liver, though at lower density than in the pancreas and gut. Liraglutide's hepatic effects appear to operate through several pathways working in the same direction.

Reduction of Hepatic Lipogenesis

Liraglutide suppresses sterol regulatory element-binding protein 1c (SREBP-1c), a transcription factor that drives de novo lipogenesis in hepatocytes. In rodent NASH models, this reduced intrahepatic triglyceride accumulation independently of caloric restriction. [5] Human mechanistic data from MRI-based studies confirm that liraglutide reduces intrahepatic fat content beyond what weight loss alone would predict.

Improvement in Insulin Sensitivity

Hyperinsulinemia drives NASH by increasing hepatic lipid uptake and suppressing mitochondrial beta-oxidation. Liraglutide's well-documented insulin-sensitizing effects, mediated partly through weight loss and partly through direct GLP-1 receptor signaling, reduce the substrate load delivered to the liver.

Attenuation of Hepatocyte Apoptosis

Liraglutide appears to reduce hepatocyte apoptosis by downregulating caspase-3 activity and increasing expression of the anti-apoptotic protein Bcl-2 in animal models. [6] Ballooning hepatocytes in NASH biopsy specimens express high levels of apoptosis markers. The reduction in ballooning seen in LEAN may partly reflect this anti-apoptotic effect rather than pure weight loss.

Anti-Inflammatory Effects

Liraglutide reduces circulating levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), both of which contribute to lobular inflammation in NASH. A 2021 meta-analysis of GLP-1 agonist trials (N=670 across 8 studies) found a pooled reduction in high-sensitivity CRP of 0.84 mg/L (95% CI: 0.52 to 1.16) compared with placebo or active comparators. [7]

Evidence Grade and Guideline Positions

The evidence supporting liraglutide (at either dose) for NASH sits at GRADE Low to Moderate. The single phase 2 RCT (LEAN, N=52) provides direct evidence with a clinically meaningful effect size, but the small sample, single dose studied (1.8 mg rather than the 3 mg Saxenda dose), and 48-week duration limit confidence. Indirect support comes from mechanistic studies, observational cohorts, and meta-analyses of GLP-1 agonists as a class.

AGA Clinical Practice Update (2023)

The American Gastroenterological Association's 2023 clinical practice update on pharmacotherapy for MASH states: "GLP-1 receptor agonists represent a promising approach for patients with MASH and coexisting obesity or type 2 diabetes, though dedicated phase 3 data are needed before routine adoption." [8] The update does not endorse a specific drug or dose.

AASLD Practice Guidance (2023)

The American Association for the Study of Liver Diseases notes in its 2023 NAFLD guidance that "weight loss of 7 to 10 percent achieved by any means, including pharmacotherapy, is associated with histologic improvement in the majority of patients." Liraglutide is listed as one agent that may support this goal but is not given a specific recommendation grade for NASH. [9]

Resmetirom as the New Reference Point

The March 2024 FDA approval of resmetirom (Rezdiffra) 80 mg or 100 mg daily for noncirrhotic NASH with stage F2 or F3 fibrosis now provides a hepatologist-driven first-line option. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg achieved NASH resolution in 25.9% of patients versus 14.2% placebo, and fibrosis improvement by one or more stages in 25.9% versus 14.7% (both P<0.001). [10] Saxenda/liraglutide does not have an equivalent phase 3 dataset.

Clinicians may still choose liraglutide when weight loss is a co-primary treatment target, when resmetirom cost or access is prohibitive, or when type 2 diabetes coexists and a GLP-1 agonist serves dual metabolic goals.

Dosing Considerations When Using Saxenda Off-Label for NASH

Saxenda is dispensed as a prefilled pen delivering 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg per injection. The approved weight-management titration schedule begins at 0.6 mg/day for week 1, with weekly 0.6 mg dose escalations to a maintenance dose of 3 mg/day. This schedule minimizes gastrointestinal side effects, which are the most common reason for discontinuation.

Titration Schedule

| Week | Daily Dose | |------|-----------| | 1 | 0.6 mg | | 2 | 1.2 mg | | 3 | 1.8 mg | | 4 | 2.4 mg | | 5 onward | 3.0 mg |

The LEAN trial used a fixed 1.8 mg dose without further escalation. Whether titrating to 3 mg produces greater histologic benefit is unknown. Prescribers using Saxenda off-label for NASH typically follow the full FDA-approved titration to 3 mg/day because the weight-loss benefit is dose-dependent and weight loss mediates at least part of the NASH benefit. [4]

Duration of Therapy

No minimum or maximum duration has been established for liraglutide in NASH. The LEAN trial ran 48 weeks. Observational data from weight-management cohorts suggest liver enzyme normalization typically occurs within 12 to 24 weeks in responders. Most hepatology-focused clinicians reassess with imaging or repeat biopsy at 48 to 72 weeks. Continuation beyond one year is reasonable if the patient is tolerating the medication and maintaining weight loss.

Contraindications and Precautions Specific to NASH Patients

Most patients with advanced NASH have metabolic comorbidities that influence prescribing. Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Pancreatitis risk warrants caution in patients with a history of acute pancreatitis, which can complicate the metabolic syndrome common in NASH.

Patients with decompensated cirrhosis were excluded from the LEAN trial. Using Saxenda in Child-Pugh B or C cirrhosis lacks any clinical trial support and should be avoided until data are available. [11]

Safety Profile in the NASH Population

The adverse effect profile of liraglutide in NASH patients mirrors its profile in approved indications, with some considerations specific to liver disease.

Gastrointestinal Adverse Effects

Nausea affects approximately 40% of patients during the titration phase and typically resolves within 4 to 8 weeks. Vomiting occurs in 15 to 20% and diarrhea in 20 to 25%. These rates come from the SCALE Obesity and Prediabetes trial (N=3,731), the key phase 3 trial supporting FDA approval. [12] In the LEAN trial (N=52), adverse event rates were similar, with nausea in 38% and vomiting in 8% of liraglutide recipients.

Liver Enzyme Monitoring

ALT and AST should be checked at baseline and every 12 weeks. In NASH, a transient aminotransferase rise during the first 4 to 8 weeks of therapy occasionally occurs, likely reflecting initial changes in hepatic lipid flux. Persistent or worsening elevation beyond 3 times the upper limit of normal warrants dose reduction or discontinuation.

Cholelithiasis

Rapid weight loss with GLP-1 agonists increases gallstone formation risk. In the SCALE trial, cholelithiasis occurred in 2.2% of liraglutide-treated patients versus 0.8% of placebo. [12] NASH patients with preexisting biliary disease warrant baseline gallbladder ultrasound before starting therapy.

How Saxenda Compares to Semaglutide for NASH

Semaglutide 2.4 mg/week (Wegovy) and oral semaglutide 50 mg/day are also under investigation for NASH. The ESSENCE trial phase 3 data, published in the New England Journal of Medicine in 2024, showed subcutaneous semaglutide 2.4 mg/week achieved NASH resolution in 62.9% of patients versus 34.3% placebo (P<0.001) and fibrosis improvement in 37.0% versus 22.5% (P<0.001) in a cohort of 800 patients. [13] These effect sizes substantially exceed the LEAN trial results for liraglutide.

Semaglutide's longer half-life, once-weekly dosing, and apparently greater efficacy in NASH may make it the preferred GLP-1 agonist for this indication once phase 3 data are formally incorporated into guidelines. As of mid-2025, semaglutide also lacks an FDA NASH approval, placing it in the same off-label category as Saxenda.

Prescribers choosing between liraglutide 3 mg and semaglutide 2.4 mg for NASH typically consider insurance coverage, patient injection frequency preference, cost, and whether the patient has an existing weight-management regimen. The ESSENCE trial data give semaglutide a stronger evidence base by volume and effect size, but direct head-to-head comparison data do not exist.

Practical Prescribing Framework for Off-Label Saxenda in NASH

The following decision points apply when a clinician considers Saxenda specifically for NASH management.

1. Confirm biopsy-proven NASH or imaging-confirmed steatosis with elevated aminotransferases and clinical risk factors, ideally with fibrosis staging by elastography or biopsy.
2. Rule out contraindications (MTC history, MEN2, history of pancreatitis, decompensated cirrhosis).
3. Document the off-label use in the medical record and obtain informed consent.
4. Start at 0.6 mg/day and titrate weekly to 3 mg/day per the standard Saxenda schedule.
5. Measure ALT, AST, fasting glucose, HbA1c, and body weight at baseline, 12 weeks, 24 weeks, and 48 weeks.
6. Consider repeat liver stiffness measurement (FibroScan or MRE) at 48 to 72 weeks to assess fibrosis response.
7. Discontinue if the patient does not achieve at least 4% weight loss by week 16, consistent with the FDA's prescribing label recommendation for weight-loss response monitoring.
8. Reassess if resmetirom or an approved NASH agent becomes available and appropriate for the patient's fibrosis stage.

The FDA's prescribing information for Saxenda specifies: "Evaluate weight loss after 16 weeks; if the patient has not lost at least 4% of baseline body weight, discontinue liraglutide 3 mg." [14] This criterion applies to off-label NASH use as well, since weight loss mediates much of the hepatic benefit.